Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8N8A6
UPID:
DDX51_HUMAN
Alternative names:
DEAD box protein 51
Alternative UPACC:
Q8N8A6; A8MPT9; Q5CZ71; Q8IXK5; Q96ED1
Background:
ATP-dependent RNA helicase DDX51, also known as DEAD box protein 51, plays a crucial role in the biogenesis of 60S ribosomal subunits. This protein is essential for the assembly and function of ribosomes, which are the cellular machines responsible for protein synthesis.
Therapeutic significance:
Understanding the role of ATP-dependent RNA helicase DDX51 could open doors to potential therapeutic strategies. Its involvement in ribosome biogenesis suggests its importance in cellular processes and disease mechanisms.